A Phase 2 interventional study of Nilotinib and Placebo to nilotinib in Pulmonary Arterial Hypertension, sponsored by Novartis Pharmaceuticals. Terminated at 13 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-01.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Pulmonary Arterial Hypertension by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Arterial Hypertension · Novartis.
Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, this one is the 7th largest by enrollment, is one of 2 that started in 2010, is one of 5 in phase 2, and was the 4th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →1 of the 12 studies in Pulmonary Arterial Hypertension by Novartis is open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 15 more countries
Ages 18–100 · Healthy volunteers
By country, each count listing its studies:
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 6
First in 2006; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 27 across the 12 interventional studies. Of the 11 that completed or were terminated, 11 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Pulmonary Arterial Hypertension by Novartis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial was to establish the safety, tolerability and PK of nilotinib in this population and to test the hypothesis that 6 months treatment with nilotinib will significantly reduce pulmonary artery resistance.
The purpose of this trial was to establish the safety, tolerability and PK of nilotinib in this population and to test the hypothesis that 6 months
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in cohort 1 were assigned to receive nilotinib 50 mg during 14 days, followed by 150 mg during 14 days, followed by 300 mg during 140 days. Participants in cohort 2 were assigned to receive nilotinib 300 mg during 168 days
Drug: Nilotinib
Participants were assigned to receive placebo to nilotinib to match 50 mg and 150 mg capsules during 168 days.
Drug: Placebo to nilotinib
Nilotinib capsules for oral administration at 50 mg, 150 mg twice a day and 300 mg (2 capsules of 150 mg) twice a day.
Placebo to nilotinib capsules for oral administration to match 50 mg, 150 mg and 300 mg capsules twice a day
Change in Pulmonary Vascular Resistance (PVR)
Change in pulmonary vascular resistance is measured via right heart catheter assessment according to local hospital procedures. It assesses several prognostic hemodynamic variables in pulmonary hypertension, including Pulmonary Vascular Resistance (PVR). Study was prematurely terminated and not powered for efficacy.
Time frame: 168 days
Change in Six-Minute Walk Distance (6MWD) From Baseline
During standardized walk course participants are connected to a portable pulse oximeter via a finger probe and instructed to walk at a comfortable speed for as far as they could manage in 6 minutes. Study was prematurely terminated and efficacy data were not analyzed or summarized
Time frame: Baseline, 168 days
Total Number of Adverse Events and Serious Adverse Events
Adverse events were summarized by the number of patients having any adverse event overall and presented in the safety section. Study was prematurely terminated.
Time frame: 168 days
23 participants were enrolled into the study (15 in cohort 1; 8 in cohort 2) 8 participants completed cohort 1 and 6 of these participants moved into cohort 1expansion. Of the 5 participants that completed Cohort 1 expansion; 3 participants went into an Extension. None of the participants completed treatment as trial was terminated
| Milestone | Cohort 1: Nilotinib | Cohort 1: Placebo | Cohort 2: Nilotinib | Cohort 2: Placebo |
|---|---|---|---|---|
| Started | 12 | 3 | 4 | 4 |
| Completed | 7 | 1 | 0 | 0 |
| Not completed | 5 | 2 | 4 | 4 |
| Withdrew: Adverse event | 3 | 1 | 1 | 0 |
| Withdrew: Withdrew consent | 2 | 0 | 0 | 0 |
| Withdrew: Administrative problems | 0 | 0 | 2 | 4 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Withdrew consent without eos 1 visit | 0 | 1 | 0 | 0 |
| Milestone | Cohort 1: Nilotinib | Cohort 1: Placebo | Cohort 2: Nilotinib | Cohort 2: Placebo |
|---|---|---|---|---|
| Started | 5 | 1 | 0 | 0 |
| Completed | 4 | 1 | 0 | 0 |
| Not completed | 1 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Milestone | Cohort 1: Nilotinib | Cohort 1: Placebo | Cohort 2: Nilotinib | Cohort 2: Placebo |
|---|---|---|---|---|
| Started | 3 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 3 | 0 | 0 | 0 |
| Withdrew: The study was terminated | 3 | 0 | 0 | 0 |
During standardized walk course participants are connected to a portable pulse oximeter via a finger probe and instructed to walk at a comfortable speed for as far as they could manage in 6 minutes. Study was prematurely terminated and efficacy data were not analyzed or summarized
No measurements were reported for this outcome.
Change in pulmonary vascular resistance is measured via right heart catheter assessment according to local hospital procedures. It assesses several prognostic hemodynamic variables in pulmonary hypertension, including Pulmonary Vascular Resistance (PVR). Study was prematurely terminated and not powered for efficacy.
No measurements were reported for this outcome.
Adverse events were summarized by the number of patients having any adverse event overall and presented in the safety section. Study was prematurely terminated.
No measurements were reported for this outcome.
Collected over Adverse events were collected over the duration of treatment 140 days for cohort 1, 168 days for cohort 2 and up to 1092 days in the extension study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Nilotinib | — | 7/12 (58.3%) | 12/12 (100%) |
| Cohort 1: Placebo | — | 1/3 (33.3%) | 1/3 (33.3%) |
| Cohort 2: Nilotinib | — | 2/4 (50%) | 3/4 (75%) |
| Cohort 2: Placebo | — | 1/4 (25%) | 4/4 (100%) |
| Event | Cohort 1: Nilotinib | Cohort 1: Placebo | Cohort 2: Nilotinib | Cohort 2: Placebo |
|---|---|---|---|---|
| Clostridial infectionInfections and infestations | 0/12 | 1/3 | 0/4 | 0/4 |
| Infusion site infectionInfections and infestations | 0/12 | 1/3 | 0/4 | 0/4 |
| SepsisInfections and infestations | 0/12 | 1/3 | 0/4 | 0/4 |
| Disseminated intravascular coagulationBlood and lymphatic system disorders | 0/12 | 0/3 | 1/4 | 0/4 |
| Cardiogenic shockCardiac disorders | 0/12 | 0/3 | 1/4 | 0/4 |
| Torsade de pointesCardiac disorders | 0/12 | 0/3 | 1/4 | 0/4 |
| Gastric ulcer haemorrhageGastrointestinal disorders | 0/12 | 0/3 | 1/4 | 0/4 |
| Cholecystitis chronicHepatobiliary disorders | 3/12 | 0/3 | 0/4 | 0/4 |
| CellulitisInfections and infestations | 0/12 | 0/3 | 1/4 | 0/4 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 0/12 | 0/3 | 0/4 | 1/4 |
| Event | Cohort 1: Nilotinib | Cohort 1: Placebo | Cohort 2: Nilotinib | Cohort 2: Placebo |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/12 | 1/3 | 3/4 | 1/4 |
| VomitingGastrointestinal disorders | 3/12 | 0/3 | 3/4 | 0/4 |
| HeadacheNervous system disorders | 6/12 | 1/3 | 3/4 | 1/4 |
| FatigueGeneral disorders | 6/12 | 0/3 | 0/4 | 0/4 |
| Blood bilirubin increasedInvestigations | 0/12 | 0/3 | 2/4 | 0/4 |
| SyncopeNervous system disorders | 0/12 | 0/3 | 0/4 | 2/4 |
| RashSkin and subcutaneous tissue disorders | 3/12 | 0/3 | 2/4 | 0/4 |
| PancytopeniaBlood and lymphatic system disorders | 1/12 | 1/3 | 0/4 | 0/4 |
| DiarrhoeaGastrointestinal disorders | 4/12 | 1/3 | 1/4 | 0/4 |
| Upper respiratory tract infectionInfections and infestations | 1/12 | 1/3 | 0/4 | 1/4 |
an end of study evaluation was only available for 14 of these patients
| Age, Continuous(Years) | Cohort 1: Nilotinib | Cohort 1: Placebo | Cohort 2: Nilotinib | Cohort 2: Placebo | Total |
|---|---|---|---|---|---|
| Mean | 52 ± 13.1 | 60 ± 6.1 | 31 ± 14.6 | 33 ± 10.2 | 32 ± 11.8 |
| Sex: Female, Male(Participants) | Cohort 1: Nilotinib | Cohort 1: Placebo | Cohort 2: Nilotinib | Cohort 2: Placebo | Total |
|---|---|---|---|---|---|
| Female | 10 | 3 | 4 | 3 | 20 |
| Male | 2 | 0 | 0 | 1 | 3 |
The record gives a start of Jul 2010, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2014, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib
Pulmonary Arterial Hypertension →